Outcome of Board Meeting

www.nureca.com Dated-21.07.2026 BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA Corporate Relations Department LIMITED Phiroze Jeejeebhoy Towers Listing Department Dalal Street, Fort Exchange Plaza, 5th Floor, Plot no. C/1 Mumbai-400001 G Block, Bandra Kurla Complex, Bandra (E) Scrip code: 543264 Mumbai-400051 Scrip Code: NURECA Subject: Outcome of Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, We wish to inform you that the Board of Directors of the Company at the meeting held today i.e. July 21, 2026 have: 1. Approved the unaudited standalone and consolidated Financial Results of the Company for the quarter ended June 30, 2026. Copies of unaudited standalone and consolidated Financial Results along with Limited Review Reports are enclosed herewith. The Board Meeting commenced at 15:00 PM and concluded at 15:40 PM. This is for your kind information and records please. Thanking You, Yours Sincerely, For Nureca Limited (Nishu Kansal) Company Secretary & Compliance Officer M. No. A33372 NURECA LIMITED Correspondence Office: SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh, India - 160009 Registered Office: Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053 Phone No. +91-172-5292900, CIN: L24304MH2016PLC320868 Q1 FY 26-27 Financial Results NURECA LIMITED Regd Office : Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053 Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868 (Amount in Rs. millions, unless otherwise stated) Statement of Unaudited Standalone Financial Results for the Quarter Ended 30 June 2026 Quarter Ended Year Ended Sr. No. Particulars 30 June 2026 31 March 2026 30 June 2025 31 March 2026 (Unaudited) (Refer Note 3) (Unaudited) (Audited) 1 Revenue from operations 4 03.96 3 54.05 343.24 1,472.10 2 Other income 1 9.18 1 0.62 25.92 83.20 3 Total income (1+2) 423.14 364.67 369.16 1,555.30 4 Expenses Purchase of stock-in-trade 2 03.71 2 30.54 253.86 1,116.23 Changes in inventories of stock-in-trade 6 7.57 6 .24 ( 10.26) ( 95.98) Employee benefits expense 4 0.27 3 6.62 40.78 154.33 Finance costs 1 .77 2 .42 2.02 10.31 Depreciation and amortization expense 5 .66 4 .32 4.79 18.48 Other expenses -Fair value changes and net loss on investments 0 .70 8 3.37 - 83.37 -Others 6 7.27 6 2.68 69.64 240.20 Total expenses 386.95 426.19 360.83 1,526.94 5 Profit / (Loss) before tax for the period (3-4) 3 6.19 ( 61.52) 8 .33 2 8.36 6 Tax expense - Current tax 1 .50 1 5.77 0.02 15.82 - Current tax related to previous year - - - ( 0.34) - Deferred tax 1 0.37 ( 11.04) 2.79 9.90 7 Profit / (Loss) after tax for the period (5-6) 2 4.32 ( 66.25) 5 .52 2 .97 8 Other comprehensive income A (i) Item that will not be reclassified to profit or loss - 0 .69 - 0.69 (ii) tax relating to items that will not be reclassified to profit or loss - ( 0.17) - ( 0.17) B (i) Item that will be reclassified to profit or loss - - - - (ii) tax relating to items that will be reclassified to profit or loss - - - - Other comprehensive income for the period (net of tax) - 0 .51 - 0 .51 9 Total comprehensive income/(loss) for the period (7+8) 2 4.32 ( 65.74) 5 .52 3 .48 10 Paid-up equity share capital (Refer note 4) 95.42 9 5.42 100.00 9 5.42 (Face value of share - Rs.10 each) 11 Other equity - - - 1 ,676.18 12 Earning per share of Rs. 10 each - Basic and diluted (in rupees) (not annualized except for the year) 2 .55 (6.95) 0.55 0.30 Notes to the Unaudited standalone financial results: 1 ThesestandalonefinancialresultsoftheCompanyhavebeenpreparedinaccordancewiththeIndianAccountingStandards(INDAS)asnotifiedbyMinistryof CorporateAffairspursuanttoSection133oftheCompaniesAct,2013readwiththeCompanies(IndianAccountingStandard)Rules,2015,asamendedandin termsofregulation33oftheSEBI(ListingObligationsandDisclosureRequirements)Regulations,2015andotheraccountingprinciplesgenerallyacceptedin India. 2 TheCompanyoperatesinsinglebusinesssegmenti.e."Homehealthcareandwellnessproducts"hencetherearenoreportablesegmentsasperIndAS108 "Operating Segments". 3 'ThefiguresforthelastquarterendedMarch31,2026isthebalancingfiguresbetweenauditedfiguresinrespectofthefullfinancialyearandthepublished,year todate,figuresuptotheendofthethirdquarteroftherelevantfinancialyear.Also,thefigures uptotheendofthethirdquarterhadonlybeenreviewedandnot subject to audit. 4 During the previous year, the Company undertook a buyback of equity shares through the tender offer route. The Company bought back equity shares at a price of ₹330 per share. The buyback was funded from the Company’s free reserves, including securities premium. The buyback was completed during the quarter ended December 31, 2025, accordingly equity shares bought back have been extinguished in accordance with applicable law and a Capital Redemption Reserve equal to the nominal value of the shares bought back has been created pursuant to Section 69 of the Companies Act, 2013. 5 Duringthepreviouyear,theCompanyhasfiledSchemeofMergerbyAbsorptionwhereinandwherebyNurecaTechnologiesPrivateLimited,awhollyowned subsidiaryoftheCompanywillbemergedwiththeCompany(“theSchemeofMerger”).TheSchemeofMergeriseffectivefromaproposedappointeddateof April1,2025,subjecttothesanctionoftheNationalCompanyLawTribunalandotherregulatoryapprovals.PendingsanctionoftheSchemeofMerger,no accounting impact has been recognized in these results. 6 TheaboveresultswerereviewedbytheAuditCommitteeandapprovedbytheBoardofDirectorsattheirrespectivemeetingheldonJuly21,2026.Thelimited review,asrequiredunderRegulation33oftheSEBI(ListingObligationsandDisclosureRequirements)Regulations,2015,hasbeencompletedbytheStatutory Auditors and they have expressed an unmodified opinion on the aforesaid results. For and on behalf of Board of Directors of Nureca Limited Saurabh Goyal Place: Chandigarh (Managing Director) Date: 21 July 2026 DIN : 00136037 Sl. n 1. Co ) WU oni rt l dN o T. r a1 d70 e4 T, o1 w7 et rh , F (l Wo To Tr ), , DND Flyway, o Sector 16, Noida 201 301 (India) Chartered Accountants T £ + n9 e1 w d( e0 l1 h20 i) @ s2 i9 n7 g 0 h0 i0 c5 o, . 9 c2 o0 m5 5 75996 www.singhico.com Independent Auditor’s Review Report on Standalone Unaudited Financial Results for the quarter ended June 30, 2026 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended To the Board of Directors of Nureca Limited 1. We have reviewed the accompanying statement of unaudited financial results of Nureca Limited (the “Company”) for the quarter ended June 30, 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”). 2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and th [Showing first 8,000 characters — download PDF for full document]